Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 7/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 7/20 | 0.52 |
| ▸ | FLT1 | P17948 | 6/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
| ▸ | STK10 | O94804 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | YES1 | P07947 | 1/20 | 0.50 |
| ▸ | LYN | P07948 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | HCK | P08631 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20216703 | 0.93 | SRC (0.53) | KDRFLT1EGFRSRCTGFBR1 | |
| SCHEMBL371845 | 0.90 | AXL (0.61) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL4407992 | 0.89 | MET (0.50) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL24444677 | 0.89 | MET (0.53) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL13787630 | 0.88 | SRC (0.50) | KDREPHA2EPHB4FLT1EGFR | |
| SCHEMBL17880567 | 0.88 | KDR (0.58) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL15338423 | 0.87 | EGFR (0.63) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL371687 | 0.87 | MET (0.48) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL13787632 | 0.84 | SRC (0.49) | KDREPHA2EPHB4SRCTGFBR1 | |
| SCHEMBL15338410 | 0.83 | EGFR (0.63) | KDRFLT1EGFRSRCTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | KDR 5/4885EPHA2 746/4885EPHB4 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.